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Background: Genomic medicine could improve precise risk 
stratification, early prevention, and personalised treatment across a 
broad spectrum of disease. As this reality approaches, questions on 
the importance of public trust arise. The success of genomic medicine 
initiatives is influenced by the public’s trust and willingness to engage. 
Specific social actors influential in the public's trust have been 
identified by the “Your DNA, Your Say” study, including doctors, 
researchers, and governments. This paper aims to identify and 
examine which specific social actors, if any, in Canada and the United 
Kingdom (UK) are the most trustworthy and influential to engage the 
public in genomic medicine research. 
Methods: Using data from the ‘Your DNA, Your Say’ study, logistic 
regression models and Pearson’s chi-square tests were conducted to 
explore trust in social actors across Canada and the UK. 
Results: The results demonstrate Canada and the UK significantly 
differ in public trust and willingness to donate. Non-profit researchers, 
domestic doctors, and personal doctors were identified to be the most 
influential and trustworthy social actors in Canada and the UK. 
Conclusions: The comparative results indicate that both countries 
would benefit from engaging the public through doctors and non-
profit researchers. The UK could additionally support public trust by 
engaging with the public through the National Health Service. 
However, the results suggest that whilst public trust is significant, it 
may be neither necessary nor sufficient in influencing willingness to 
donate. Future research could do well to investigate how the 
importance of public trust compares in countries with lower public 
trust.
Keywords 
genomics, public trust, data sharing, Canada, United Kingdom, 
personalised medicine, personalized medicine, genomic medicine
Open Peer Review








20 May 2021 report report report
Ruth Horn, University of Oxford, Oxford, UK1. 
Alessandro Blasimme , ETH Zürich, 
Zürich, Switzerland
2. 
Mavis Machirori, Ada Lovelace Institute, 
London, UK
3. 
Any reports and responses or comments on the 
article can be found at the end of the article.
 
Page 1 of 19
Wellcome Open Research 2021, 6:124 Last updated: 09 JUL 2021
Corresponding author: Richard Milne (richard.milne@wellcomeconnectingscience.org)
Author roles: Savić-Kallesøe S: Conceptualization, Formal Analysis, Software, Visualization, Writing – Original Draft Preparation, Writing 
– Review & Editing; Middleton A: Funding Acquisition, Investigation, Methodology, Project Administration; Milne R: Supervision, Writing 
– Review & Editing
Competing interests: No competing interests were disclosed.
Grant information: This work was supported by the Wellcome Trust [206194]. 
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright: © 2021 Savić-Kallesøe S et al. This is an open access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Savić-Kallesøe S, Middleton A and Milne R. Public trust and genomic medicine in Canada and the UK 
[version 2; peer review: 3 approved] Wellcome Open Research 2021, 6:124 https://doi.org/10.12688/wellcomeopenres.16831.2
First published: 20 May 2021, 6:124 https://doi.org/10.12688/wellcomeopenres.16831.1 
 
Page 2 of 19
Wellcome Open Research 2021, 6:124 Last updated: 09 JUL 2021
Introduction
Genomic medicine and public health
The sharing of patient data, especially genomic data, across 
a healthcare system is pertinent for the improvement of 
population screening and patient care. Broadly defined, genomic 
data refers to an individual’s sequenced DNA1. Genomic medi-
cine, a subset of precision medicine, pertains to using an 
individual’s genomic data to guide clinical care, including 
screening, diagnostics, and treatments2. Medical information 
includes individuals’ demographic profile and medical history of 
diagnostics, diseases, and treatments3.
At the population level, genomic medicine may revolution-
ize how we identify and care for populations at high-risk for an 
array of diseases. A key public health implication of genomic 
medicine is population risk stratification based on genetic 
predisposition, allowing for earlier, more precise, and more 
cost-effective intervention4 and the potential to improve popu-
lation screening for a spectrum of diseases. Genomic medicine 
integrated into routine healthcare would afford patients robust 
disease risk prediction, improved precision and positive predict-
ability value of diagnostics, and medication regimes tailored to 
their genetic profile5.
Integrating genomic medicine into routine healthcare involves 
collecting, storing, and analyzing data from the genomes of a 
large number of individuals. Consequently, many countries have 
pledged to utilize genomic medicine into healthcare through 
large-scale sequencing initiatives involving at least 100,000 citi-
zens, including the UK, Saudi Arabia, Turkey, France, and the 
United States (which aims to a sequence a million genomes)6.
Public trust
The success of genomic medicine depends on the willingness 
of the public, as patients and non-patients, to make genomic 
and health information about themselves available to others. 
A key factor in this is people’s trust in the government’s and 
healthcare system’s ability to securely store, disseminate, and 
analyze data. While difficult to measure, evidence suggests 
that public trust in government in Anglo countries, including 
the US, Canada, and the UK, has been generally declining7.
In the UK, the ‘care.data’ initiative announced in 2013 was 
meant to facilitate health service and provision planning by 
extracting and pooling patient data from general practitioner 
offices into a national database8,9. The default ‘opt-out’ of the 
programme, which required action to withdraw consent, was 
met with controversy and public disapproval9,10. The care.data 
initiative was abandoned in 2014, which was largely attrib-
uted to its failure to gain the confidence of patients, healthcare 
professionals, and citizens in its procurement of consent and 
management of data.
Canada faces systemic barriers in patient data sharing, largely 
due to its decentralized structure; instead of a single national 
healthcare system, there are 10 provincial, three territorial, 
and one federal healthcare systems, each providing care for 
different groups of people, typically based on region11. Each 
system is the sole owner of its health-related data, including sur-
veillance and patient data12. Currently, there is no pan-Canadian 
electronic medical data system, whereby a patient’s data is 
accessible anywhere in the nation13. This results in patients 
carrying the burden of recording their medical history and 
presenting it to each new health professional they encoun-
ter. However, the lack of successful cooperation between enti-
ties results in a patchwork of electronic medical record systems 
and contributes to patient burden, as well as fading trust in 
Canada’s healthcare7,14,15.
Failed implementations such as this demonstrate the importance 
of public trust in the success of public health initiatives. The 
influence of the public’s trust was also evident in the 2009 
H1N1 pandemic, when hampered vaccine uptake was attributed 
to distrust in government and the scientific community, vocal-
ised by groups such as anti-vaccine followings16. Similarly, the 
efficacy of large-scale lockdowns instated during COVID-19 
to prevent the transmission of SARS-CoV-2 was attenuated as 
public trust and compliance wavered17,18.
Public confidence in institutional healthcare is also crucial 
for effective routine patient-doctor relationships. There is evi-
dence indicating that trust in institutional healthcare, such as 
hospitals and insurance providers, affects individual’s willing-
ness to access care17. There is evidence of a general lack of trust 
between the public and healthcare system, which may make 
it more difficult to integrate personal information into routine 
clinical care19,20. In addition, marginalised populations fac-
ing systemic bias and who may have personal experience 
with discrimination may develop distrust in institutions and, 
consequently, access health services disproportionately less17. 
This is reflected in inequitable outcomes, such as poor adher-
ence to recommendations and worse self-reported health, among 
marginalised communities21–24.
Fostering public trust in genomic medicine research poses addi-
tional challenges compared to those of other public health initia-
tives. These differences include that the implications of genomic 
          Amendments from Version 1
This version includes updates made according to the reviewers’ 
feedback, including:
Updating “Anglo-Saxon” countries to “Anglo” countries 
(introduction);
Providing further context of the public’s support of the UK NHS 
(using the King’s Fund 2019 survey) (discussion);
Clarification of social actors (introduction); 
Elaboration of the role of for-profit researchers (discussion), 
clarification of the domestic, rather than international, nature of 
data sharing (discussion); and
Clarification of the research, rather than clinical, purposes of 
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data extend beyond the patient and to their biological 
relatives25. Additionally, due to its identifiable nature, DNA infor-
mation may require exceptional protection25. For these reasons, 
the integration of genomic medicine into mainstream health-
care must be purposefully and thoughtfully informed by the 
public voice. At the core of its successful integration is a trusting 
relationship between the public and the healthcare system.
Canada and the UK
The “Your DNA, Your Say” (YDYS) study aims to under-
stand the public’s inclination to participate in data sharing based 
on their willingness to donate their DNA information; it has 
identified willingness to donate DNA to be related to general 
public trust in social actors, such as the government, non-profit 
researchers, and doctors across 22 countries26,27. These specific 
social actors were chosen to capture the individuals and insti-
tutions involved in collecting and using genomic and health 
data. Prior publications have investigated how trust and willing-
ness to donate trend across the 22 countries and have examined 
the Anglo countries as a cluster. These analyses suggest that the 
public’s trust plays a key role in the population’s willingness 
to donate DNA; across all countries examined in the YDYS 
study, overall trust was found to be positively associated with 
willingness to donate28. This trend is also evident within the 
grouped analysis of Canada, the USA, Australia, and the UK26.
Previous analyses of YDYS data indicated that Canada and 
the UK have similarly influential social actors in relation to 
health data26. This could be linked to their structurally similar 
universal healthcare systems, similar legal systems, and deep 
shared historical ties. Given this, we would expect that Canada 
and the UK would have similar results in public trust and 
willingness to donate DNA information. Indeed, further analy-
ses have suggested that Canada and the UK may be particu-
larly closely related in terms of how respondents perceive the 
trustworthiness of data institutions28,29. A side-by-side comparison 
of Canada and the UK offer the opportunity to examine whether 
and how public trust plays different roles in genomic medicine 
research within two similar countries. In this paper, we inves-
tigate which social actors, if any, in Canada and the UK are the 
most trusted and may be most influential to effectively engage 
the public in genomic medicine research. We develop a com-
parative analysis of the UK and Canada to understand the 
nuances of the public’s trust in social actors involved in genomic 
medicine research and patient data sharing, such as the govern-
ment, doctors, and the healthcare system. The implications of 
such findings would contribute to the evidence base for future 
informed patient data sharing initiatives. For a larger compari-
son across countries beyond Canada and the UK, please refer 
to existing YDYS publications28.
Objectives
The YDYS study is the source of data for this paper, which 
includes survey responses from 36,268 individuals across 22 
countries, collected from 2017 and onwards. The purpose of the 
YDYS study is to assess: the public’s attitudes and trust towards 
donating and sharing of genomic information; the character-
istics of those most and least willing to donate; the charac-
teristics of those most and least trusting of government and 
medical social actors. The research question posed in this 
paper is “Are there differences in public trust between Canada 
and the UK and might they affect the public’s willingness to 
donate DNA information for genomic medicine research?” 
Considering that the data are cross-sectional and ecological in 
nature, this investigation is meant to be hypothesis-generating 
and exploratory rather than conclusive.
Specifically, this paper aims to:
1.  Compare proportions of the public’s trust in and the 
influences of social actors in willingness to donate 
between Canada and the UK.
2.  Assess whether these differences in public trust 
warrant separate tailored strategies in engaging the 
public genomic medicine research.
3.  Identify potential structures that could explain the 
variation in public trust and willingness to donate 
between Canada and the UK. 
Methods
Data from the YDYS study were used for this paper, the meth-
odological details of which have been published separately30. 
Responses from 36,268 participants were collected through 
an online survey available in 14 languages across 22 
countries. Of those, 2,961 participants were in Canada and 3,406 
in the UK, totalling 6,373 participants. Responses were col-
lected by a market research company, Dynata, in 2017. The 
samples are evaluated to be representative, based on compari-
sons with national census data of population age and gender 
structure. Participants were offered a small financial incentive 
(< £1). The recruitment method did not allow for a known non-
response rate. Consisting of 29 questions, the survey31, which 
can be accessed at YourDNAYourSay.org, takes approximately 
15–20 minutes to complete.
Measure definitions
Trust. Participants’ overall trust and trust in specific social 
actors were both assessed. Participants were asked whether 
they generally trust the following social actors: their doctor, any 
domestic doctor, any international doctor, their country’s gov-
ernment, for-profit researchers, and non-profit researchers. 
Non-profit researchers included university and publicly 
funded researchers. For-profit researchers included research-
ers funded by private companies spanning across a wide scope 
of industries, such as pharmaceutical, drug discovery, diagnos-
tic, and healthcare technology development. Response options 
included “Yes”, “No”, and “Unsure”. The “No” and “Unsure” 
responses were combined for analysis, reflecting the active 
choice nature of trust discussed above, our interest in inves-
tigating the influence of active trust on willingness to donate 
and to improve the statistical power of tests drawing on 
respondents who did not actively trust. Participants were defined 
as “generally trusting” if they reported “Yes” to trusting at 
least two social actors. In our analysis, we treat trust in cer-
tain social actors as proxies for trust in the national healthcare 
system (trust in any domestic doctor) and trust in the medical 
profession (any international doctor).
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Willingness to donate DNA. Participants were categorised as 
generally willing to donate if they self-reported willing to donate 
to at least two of the following: medical doctors, for-profit 
researchers, or non-profit researchers. Those who did not 
were categorised as not generally willing to donate.
Familiarity with genetics. Participants self-reported whether 
they were familiar with DNA, genetics, or genomics. Those who 
reported familiarity were asked for further detail, and those with 
knowledge of DNA through family or personal medical his-
tory or their work (i.e., genetics counsellor, genetic researcher, 
etc.) were identified as having ‘personal familiarity’. Those who 
did not identify being familiar with genetics were categorised 
as ‘unfamiliar’.
DNA status. Participants were asked whether they regard 
DNA information to be different from other medical informa-
tion. Participants were categorised as either regarding DNA 
information different from other medical information, the same, 
or unsure. For analysis, ‘same’ and ‘unsure’ responses were 
combined as we are interested in investigating those who see 
DNA information as different.
Analysis
The statistical software Stata, version 16.1, was used to clean 
the data and conduct analysis. A logistic regression model 
was created to explore whether public trust is influential in 
willingness to donate DNA. Pearson’s chi-squared tests were 
performed to identify whether there were statistical differences 
in the proportions of those willing to donate DNA informa-
tion or of those who are overall trusting between Canada and the 
UK. Two logistic regression models, one for each country, 
were created to investigate how social actors and other fac-
tors might influence willingness to donate in Canada and the 
UK. Factors included familiarity of genetics, perception of DNA 
information as different from other medical information, and 
trust in specific social actors. Social actors included the respond-
ent’s doctor, any domestic doctor, any international doc-
tor, their country’s government, a for-profit researcher, and 
non-profit researcher. Social actors with discordant significance 
between the country models were further investigated by chi-
square tests, exploring whether Canada and the UK significantly 
differ in proportions who trust these social actors, including 
doctors and for-profit researchers.
Ethics
The online survey is fully anonymous. Participants are informed 
that their consent is given when they choose to click off 
the landing page and start answering the questions. On the land-
ing page, the purpose of the project is explained as well as what 
participation involves; participants have a choice at any stage 
within the survey to stop answering the questions and with-
draw. The online project is physically based at the Wellcome 
Genome Campus with all data collected and stored in 
encrypted files at the Wellcome Sanger Institute in Cambridge. 
As part of the conditions of research delivery at this research 
institution, the project passed ethical review by the Human 
Materials and Data Management Committee of the Wellcome 
Sanger Institute (Registration Number: 16/029), as well as 
legal review to ensure that it was compliant with ethical and 
legal standards for participant involvement, data collection, and 
storage. 
Results
Trust and willingness to donate DNA
As mentioned in the introduction, existing literature has identi-
fied a positive association between overall trust and willingness 
to donate genomic data within Canada and the UK. Pooling the 
Canadian and UK samples, the logistic regression model in 
Table 1 suggests that overall trust is significantly associated with 
willingness to donate; the odds that an individual willing to 








Are generally trusting* 
      (Ref = not trusting or unsure)
4.61 0.000 (4.13 – 5.15)
Familiar with genetics 
      (Ref = no familiarity with genetics)
1.97 0.000 (1.76 – 2.21)
Regard DNA as different from other medical information 
      (Ref = regarding medical and DNA information to be the same)
1.53 0.000 (1.37 – 1.71)
Country 
      (Ref = Canada)
0.75 0.000 (0.67 – 0.83)
Constant 0.24 0.000 (0.21 – 0.27)
* Defined as participants who trust at least two of the following: their doctor, any domestic doctor, their 
country’s government, domestic for-profit researchers, or domestic non-profit researchers.
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likely than not generally trusting (95% CI, 4.13-5.15) (Table 1). 
In both countries almost half of Canadian and UK respondents 
report general trust in multiple potential data users (Canada: 
48.56%; UK: 53.82%)31.
Comparing Canada and the UK
Chi-square tests were conducted to compare how Canada and 
the UK differ in willingness to donate DNA and trust (Table 2). 
The results indicate there to be a significant difference in over-
all trust between Canada (48.56%) and the UK (53.82%) 
(Table 2). A significantly greater proportion of the Canadian 
sample (45.96%) was willing to donate compared to the UK 
(40.49%). Considering there are significant differences in the 
degree of trust, logistic regression models were developed to 
investigate the influences of trust on willingness to donate in the 













Trust their doctor 1.78 0.000 (1.43 – 2.21) 1.97 0.000 (1.56 – 2.48)
Trust any domestic doctor 1.53 0.000 (1.24 – 1.87) 1.38 0.001 (1.15 – 1.66)
Trust any international doctor 1.16 0.297 (0.87 – 1.55) 1.13 0.296 (0.90 – 1.44)
Trust non–profit researchers 3.38 0.000 (2.79 – 4.08) 3.91 0.000 (3.26 – 4.69)
Trust for–profit researchers 1.17 0.000 (1.27 – 2.34) 1.31 0.079 (0.97 – 1.78)
Trust their country’s government 
      (Ref = not trusting or unsure)
1.47 0.001 (1.17 – 1.86) 1.58 0.000 (1.25 – 1.98)
Familiar with genetics 
      (Ref = no familiarity with genetics)
1.72 0.000 (1.46 – 2.04) 2.04 0.000 (1.73 – 2.40)
Regard DNA as different from other 
medical information 
       (Ref = regarding medical and DNA 
information to be the same)
1.42 0.000 (1.20 – 1.68) 1.53 0.000 (1.31 – 1.79)
Constant 0.17 0.000 (0.14 – 0.21) 0.12 0.000 (0.09 – 0.14)







Participants who: N % N % P
Are generally trusting* 1,438 48.56 1,833 53.82 0.000
Are willing to donate DNA 1,361 45.96 1,379 40.49 0.000
Trust their doctor 2,276 76.87 2,638 77.45 0.579
Trust any domestic doctor 1,054 35.60 1,597 46.89 0.000
Trust any international doctor 422 14.25 548 16.09 0.042
Trust non-profit researchers 1,110 37.49 1,124 33.00 0.000
Trust for-profit researchers 345 11.65 330 9.69 0.011
Trust their country’s government 570 19.25 558 16.38 0.003
* Defined as participants who trust at least two of the following: their doctor, any 
domestic doctor, their country’s government, domestic for-profit researchers, or 
domestic non-profit researchers.
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Separate logistic regression models were created for the Canadian 
and UK samples (Table 3). Terms predicting willingness 
to donate included trust in: one’s doctor, any domestic doc-
tor, any international doctor, the country’s government, 
for-profit researchers, non-profit researchers; familiarity with 
genetics; and whether they saw DNA information as different 
from other medical information. All terms were significantly 
associated with willingness to donate in both country mod-
els, except for trust in any international doctor, which was not 
significant in either country’s model (Canada: OR 1.16, 95% 
CI 0.87-1.55; UK: OR 1.13, 95% CI 0.90-1.43). Trust in 
domestic doctors was found to be influential in willing-
ness to donate DNA in both countries (Table 3); the odds of 
a willing Canadian to be trusting of any domestic doctor are 
1.53 times than to not be willing to donate (95% CI 1.24-1.87) 
and 1.97 times for a willing individual in the UK (95% 
CI 1.56-2.48). Trust in for-profit researchers was found to be 
significant in predicting willingness to donate in the Canadian 
model (OR 1.73, 95% CI 1.27-2.34) but not the UK model 
(OR 1.31, 95% CI 0.97-1.78). Doctors and for-profit researchers 
were of particular interest, suggesting they may contribute 
to differences in trust and willingness to donate between 
Canada and the UK. 
Doctors. The proportions of those who trust their doctor, any 
doctor, and any international doctor were compared between 
Canada and the UK (Table 2). Personal doctors hold the high-
est level of public trust and there is no evidence to suggest that 
the proportions differ significantly between Canada (76.87%) 
and the UK (77.45%). The regression models in Table 3 
suggest that trust in any domestic doctor is a significant explan-
atory variable in both Canada and the UK. However, the 
chi-square results suggest that a significantly greater propor-
tion of the UK sample (46.89%) trust any domestic doctor com-
pared to the Canadian sample (35.60%). Trust in international 
doctors was not a significant explanatory variable in either 
model and there was no evidence to suggest there to be a dif-
ference in the proportions who trust them between Canada and 
the UK (Canada: 14.25%; UK: 16.09%).
A chi-square test was run to assess differences in the propor-
tion who trust in their doctor (Table 4). The oldest group, over 
60 years, had significantly higher proportions of trust. Sig-
nificant differences were also found in trusting domestic 
doctors across age in the Canadian sample (P=0.003) (Table 4); 
the age category with the greatest trust in domestic doctors 
is the 31–40-year group (40.10%). No significant differences 
were found in trusting domestic doctors across age categories in 
the UK sample (P=0.089).
For-profit researchers. Trust in for-profit researchers was 
significant in willingness to donate in Canada but not the UK 
(Table 3). This discordance of significance was further assessed 
with chi-square tests and comparisons to trust in non-profit 
researchers. In both Canada and the UK, the proportion who 
trust non-profit researchers (Canada: 37.49%; UK: 33.0%) is 
significantly greater than the proportion who trust for-profit 
researchers (Canada: 11.65%; UK: 9.69%) (Table 2). How-
ever, these proportions who trust either for-profit or non-profit 
researchers differ significantly between Canada and the UK.





Those who trust their doctor: N n % N n %
30 years and under 451 631 71.47 702 912 76.97
31 – 40 years 452 606 74.59 504 690 73.04
41 – 50 years 404 528 76.52 476 619 76.90
51 – 60 years 447 567 78.84 462 588 78.57
Over 60 years 522 629 82.99 494 597 82.75
P = 0.000 P = 0.001
Those who trust any domestic doctor: N n % N n %
30 years and under 236 631 37.40 460 912 50.44
31 – 40 years 243 606 40.10 324 690 46.96
41 – 50 years 198 528 37.50 289 619 46.69
51 – 60 years 181 567 31.92 258 588 43.88
Over 60 years 196 629 31.16 266 597 44.56
P = 0.003 P = 0.089
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Discussion
Identifying social actors who hold the greatest public trust and 
influence has the potential to support the success of genomic 
medicine and data sharing initiatives, consequently improv-
ing the precision of population risk stratification, earlier pre-
ventative care, and, consequently, lightening healthcare burdens. 
The paper has aimed to understand the nuances in the public’s 
trust of social actors in Canada and the UK, two countries with 
relatively high levels of public trust that previous analyses have 
suggested are similar. Doctors and for-profit researchers were 
identified to be of interest in the logistic regression models.
Existing YDYS publications suggest overall trust in social 
actors to be influential in one’s willingness to donate. Con-
sidering that the proportions who generally trust social actors 
significantly differ between Canada (48.56%) and the UK 
(53.82%), the UK sample was expected to have a higher pro-
portion of those willing to donate (Table 2). Contrary to expec-
tation, the results suggest that the UK sample has a smaller 
proportion of participants willing to donate (40.49%) compared 
to the Canadian sample (45.96%) (Table 2).
The Canadian sample displays a significantly higher degree of 
willingness to donate and trust in researchers. Personal doctors 
hold the highest degree of public trust, followed by non-profit 
researchers. Trust in personal doctors varies across age, with 
a greater proportion of older patients (60 years and above) 
trusting their doctor. Like the UK sample, trust in non-profit 
researchers appears to have the strongest association with will-
ingness to donate. Based on this evidence, personal doctors 
and non-profit researchers are the most influential and trust-
worthy social actors with regards to encouraging the public to 
donate genomic information for medical research in Canada.
In the UK sample, a significantly greater proportion were gen-
erally trusting, trust their own doctor, and trust any domes-
tic doctor, suggesting a strong degree of public trust in the 
healthcare system. A trend of trust in personal doctors was 
observed, with the oldest participants (>60 years) displaying 
the greatest proportion who trust in their doctor. A similar trend 
in trust for domestic doctors was not found, with no particu-
lar age group displaying a significantly different level of trust. 
Similar to the Canadian sample, trust in non-profit research-
ers among the UK participants has the greatest association with 
willingness to donate. However, unlike its Canadian counterpart, 
trust in for-profit researchers was not found to be significantly 
associated with willingness to donate.
Trust in doctors
Trust in three types of doctors were investigated, each repre-
senting a different relation with the public. We can understand 
participants’ trust in any domestic doctors as reflecting their 
overall trust in the country’s healthcare system, while trust in 
any international doctor might be understood as a proxy of 
their trust in the medical profession.
In Canada and the UK, an individual’s own doctor holds influ-
ential power on participants’ willingness to donate and the 
highest degree of trust. Trust in international doctors was not 
found to be influential in willingness to donate in either 
country. Trust tends to attenuate as social relationships become 
more distant32, so it is expected that personal doctors would 
hold greater trust compared to domestic doctors, and for 
domestic doctors to hold more trust compared to international 
doctors. The proportions who trust doctors in Canada and the 
UK are similar, except for trust in domestic doctors; while pub-
lic trust in domestic doctors is influential in both samples, it is 
significantly higher in the UK. With regards to the degree of 
influence on participants’ willingness to donate, personal, 
domestic, and international doctors held similar levels of 
influence between Canada and the UK.
Variation across age. Trust in personal doctors significantly 
varies across age. The age group with the greatest proportion 
trusting one’s doctor is the oldest group (>60 years), in 
both Canada and the UK, which is consistent with the posi-
tive association between age and trust in doctors previously 
identified33. Variation in trust across age also exists amongst 
domestic doctors; the second youngest group (31–40 years) in 
the Canadian sample had the highest proportion of those who 
trust domestic doctors, suggesting they may be the most trust-
ing of the healthcare system. However, there was no evidence to 
suggest a trend across age in the UK sample.
Trust in domestic researchers
Trust in domestic non-profit researchers was found to be the 
most influential for willingness to donate in Canada and in the 
UK (Table 3). Yet non-profit researchers were the second most 
trusted social actor in Canada (following personal doctors and 
followed by domestic doctors) and third most trusted in the UK 
(following personal doctors and domestic doctors). The dif-
ference between Canada and the UK in relative trust between 
non-profit researchers and domestic doctors further suggests 
that the healthcare system holds stronger influence on the 
willingness to donate DNA in the UK.
The influential role of non-profit researchers in public trust 
in both countries might be associated with their obligation to 
safeguard and role in analysing patient data34. Similarly, doc-
tors might hold high trust due to their role in applying genomic 
data findings to medical recommendations34. The stronger 
influence of trust in non-profit researchers over personal doc-
tors in both countries might highlight the public’s interest in the 
safeguarding and analysis of their data.
Why is it that trust in domestic non-profit researchers appears 
more influential in willingness to donate than trust in domestic 
for-profit researchers? One explanation may be the importance 
of trust in, and alignment of, motives35. Thus, for non-profit 
research, which is often founded on principles of altruism or 
solidarity, it may be more important that there is a perceived 
alignment of values between the research population and the 
researcher. The donation of data to non-profit researchers, relies 
on faith that non-profit researchers will act in the interests of 
the public good. Conversely, a general lack of public trust and 
engagement has been observed for for-profit research initiatives 
that use patient data, yet trust seems less influential in shap-
ing the willingness to donate to these actors36,37. It also appears 
that the purpose of data sharing influences the public’s trust of 
for-profit researchers; sharing health data with commercial 
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companies for patient rather business purposes may be more 
acceptable to members of the public38. By focusing healthcare 
and commercial partnerships on patient-centered benefits and 
data protection, further public trust in for-profit researchers may 
be garnered.
These findings suggest that, in the development of public 
genomic medicine initiatives, value alignment between social 
actors and the public is influential. Moreover, trustworthiness of 
these initiatives may be reliant on their being guided by 
non-profit rather than for-profit initiatives.
Implications
The findings presented here have implications for the develop-
ment of policy and practice in engaging publics with genomic 
medicine research. First among these is the role of doctors 
and the health system as the interface between the public and 
genomic medicine initiatives. Doctors are a key social actor 
and potential leverage point in engaging the public in genomic 
medicine research as they, by professional nature, often act as 
an interface between the public and the healthcare system. How-
ever, there are complications in engaging the public through 
personal doctors. The most pertinent being that not everyone 
has a designated doctor (‘family’ doctor), and that those who 
are more disadvantaged are less likely to have a doctor33,39. If 
engagement methods rely on patients receiving information 
from their doctor, and if discrepancies exist in how primary 
care is accessed exists, this will systematically disfavour those 
who are already more disadvantaged. The second consid-
eration is that depending on individual doctors to inform their 
patients of genomic medicine research in addition to their duties 
within the limited appointment time may be infeasible and 
burdensome. Lastly, relying on individual doctors to dissemi-
nate information will inevitably foster inconsistency; it would 
also be impractical to guide efforts pursued by individual 
doctors rather than to steer a single, composite effort by the 
healthcare system.
Considering that public trust in the healthcare system is a 
distinguishing feature between Canada and the UK, policy deci-
sions surrounding the implementations of genomic medicine 
might reflect the social actors that garner the most trust. The 
UK might best encourage public trust through individual doc-
tor-patient relations. Considering the high level of public support 
for, and satisfaction with, the National Health Service (NHS)40, 
mass-media campaigns carried out by the NHS could contrib-
ute to establishing public trust. Comparatively, Canada might 
more effectively focus on patients’ relationships with personal 
doctors and with non-profit researchers. This might involve 
doctors informing patients how their genomic information 
could affect medical recommendations.
Necessity vs. sufficiency of public trust
However, it is also important to recognise that our findings 
show that while public trust is influential, it may not always 
be necessary. The public regularly interacts with social actors 
with whom they do not share values with or who are not widely 
trusted. The nuances of trust also raise questions regarding 
its sufficiency for willingness to donate. The evidence 
suggests that the Canadian public is generally more trusting of 
both non-profit and for-profit researchers. This could be explained 
if the Canadian sample were more generally trusting. How-
ever, the Canadian sample has a smaller proportion who trust 
social actors overall. Whilst counterintuitive, there are likely 
other factors influencing trust. One important aspect is that 
trust is far more nuanced than we can capture in this study. 
Trust is associated with increased odds to willingness to 
donate and there are significant differences in the degrees of 
trust across Canada and the UK. But, as demonstrated in the 
results, high levels of public trust do not guarantee high levels 
of willingness to donate; people are willing to donate even when 
they do not trust, and it cannot be guaranteed that those who 
do trust will also be willing to donate. Public trust is not 
sufficient for willingness to donate. Overall trust may not be 
determinant in willingness to donate, but trust in the social 
actors involved in the collection, management, storage, and 
application of one’s genomic information is influential.
Limitations
A key vulnerability of this study is reductionism. Trust is 
complex, dynamic, and context dependent, making it difficult 
to reflect through an exploratory quantitative study. Trusting 
multiple specific social actors does not necessarily equate to 
having a high level of general trust. This study focused on 
identifying social actors who hold the public’s trust. In the 
exploration of active trust, responses indicating distrust and 
uncertainty were pooled during statistical analysis. By doing 
so, this study did not identify social actors who harbour active 
distrust. Further investigations could compare levels of public 
trust and distrust of social actors. Identifying characteristics 
that make social actors more or less trustworthy would be per-
tinent in the implementation of initiatives that rely on high 
public trust to be effective. Considering there are no previous pub-
lications on the topic of public trust and attitudes towards genomic 
medicine research using a global survey, evaluating validity by 
comparing to similar studies is not feasible. Additionally, using 
an online survey as the method of data collection is limited in 
that non-response rates are unknown and populations with poor 
access to the internet are not represented. Lastly, by nature of this 
study being of cross-sectional design, the questions posed are 
exploratory in nature; the results speak only to associations and 
are not conclusive. 
Conclusion
Genomic medicine has the potential to improve precise risk 
stratification, early prevention, and specialised treatment. 
However, the public’s trust is consequential for its efficacy. 
The aim of this research was to investigate how Canada and the 
UK differ in willingness to donate DNA and how willingness 
is influenced by trust in social actors. Evidence suggests that 
public trust in Canada and the UK differ enough to justify tai-
loring separate methods for engaging the public in genomic 
medicine research; the UK could benefit more from a mix of 
personal doctor and healthcare system engagement, whereas 
Canada could benefit from a method which focuses on engag-
ing the public through their doctors. Both countries could 
gain from involving non-profit researchers, as trust in them 
is the most strongly associated with willingness to donate in 
Canada and the UK. Specific examples could include provid-
ing opportunities for researchers to talk about their work and 
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